NEW YORK and PETACH TIKVAH, Israel, May 7, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report first quarter 2015 financial results on Thursday, May 14, 2015.  The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. Eastern Time to discuss the results.

Conference Call & Webcast

Thursday, May 14, 2015 at 8:30 a.m. ET/5:30 a.m. PT
   Domestic:                            888-299-7209
   International:                        719-325-2244
   Conference ID:                     9028301
   Webcast:                            http://public.viavid.com/player/index.php?id=114583

Replay

Available through May 28, 2015
   Domestic:                              877-870-5176
   International:                          858-384-5517
   Conference ID:                       9028301

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn™ has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.  For more information, visit the company's website at www.brainstorm-cell.com.

Logo - http://photos.prnewswire.com/prnh/20141006/150511

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-report-first-quarter-2015-financial-results-on-thursday-may-14-300079507.html

SOURCE BrainStorm Cell Therapeutics Inc.